These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 22005056)

  • 41. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
    Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
    J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
    Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
    J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metallo-beta-lactamases: the quiet before the storm?
    Walsh TR; Toleman MA; Poirel L; Nordmann P
    Clin Microbiol Rev; 2005 Apr; 18(2):306-25. PubMed ID: 15831827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A convenient microbiological assay employing cell-free extracts for the rapid characterization of Gram-negative carbapenemase producers.
    Marchiaro P; Ballerini V; Spalding T; Cera G; Mussi MA; Morán-Barrio J; Vila AJ; Viale AM; Limansky AS
    J Antimicrob Chemother; 2008 Aug; 62(2):336-44. PubMed ID: 18456651
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases.
    Sakurai Y; Yoshida Y; Saitoh K; Nemoto M; Yamaguchi A; Sawai T
    J Antibiot (Tokyo); 1990 Apr; 43(4):403-10. PubMed ID: 2112533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Approved Drugs Containing Thiols as Inhibitors of Metallo-β-lactamases: Strategy To Combat Multidrug-Resistant Bacteria.
    Klingler FM; Wichelhaus TA; Frank D; Cuesta-Bernal J; El-Delik J; Müller HF; Sjuts H; Göttig S; Koenigs A; Pos KM; Pogoryelov D; Proschak E
    J Med Chem; 2015 Apr; 58(8):3626-30. PubMed ID: 25815530
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The rise of resistant gram-negative bacteria].
    Kuijper EJ; van Dissel JT
    Ned Tijdschr Geneeskd; 2010; 154(45):A2868. PubMed ID: 21118590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
    Barcelona L; Marín M; Stamboulian D
    Medicina (B Aires); 2008; 68(1):65-74. PubMed ID: 18416324
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential Inhibitors Against NDM-1 Type Metallo-β-Lactamases: An Overview.
    Sharma S; Sharma S; Singh PP; Khan IA
    Microb Drug Resist; 2020 Dec; 26(12):1568-1588. PubMed ID: 32486911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options.
    Jean SS; Lee WS; Lam C; Hsu CW; Chen RJ; Hsueh PR
    Future Microbiol; 2015; 10(3):407-25. PubMed ID: 25812463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NDM-8 metallo-β-lactamase in a multidrug-resistant Escherichia coli strain isolated in Nepal.
    Tada T; Miyoshi-Akiyama T; Dahal RK; Sah MK; Ohara H; Kirikae T; Pokhrel BM
    Antimicrob Agents Chemother; 2013 May; 57(5):2394-6. PubMed ID: 23459485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Delhi metallo-β-lactamase-1: structure, inhibitors and detection of producers.
    Groundwater PW; Xu S; Lai F; Váradi L; Tan J; Perry JD; Hibbs DE
    Future Med Chem; 2016 Jun; 8(9):993-1012. PubMed ID: 27253479
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation of
    Zhao X; Jin Y; Bai F; Cheng Z; Wu W; Pan X
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0042122. PubMed ID: 35695577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. β-Lactamase inhibitors: a review of the patent literature (2010 - 2013).
    Buynak JD
    Expert Opin Ther Pat; 2013 Nov; 23(11):1469-81. PubMed ID: 23967802
    [TBL] [Abstract][Full Text] [Related]  

  • 58. E152A substitution drastically affects NDM-5 activity.
    Kumar G; Issa B; Kar D; Biswal S; Ghosh AS
    FEMS Microbiol Lett; 2017 Feb; 364(3):. PubMed ID: 28087620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repurposing Peptidomimetic as Potential Inhibitor of New Delhi Metallo-β-lactamases in Gram-Negative Bacteria.
    Liu Y; Yang K; Jia Y; Wang Z
    ACS Infect Dis; 2019 Dec; 5(12):2061-2066. PubMed ID: 31637907
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment options for extended-spectrum beta-lactamase-producers.
    Essack SY
    FEMS Microbiol Lett; 2000 Sep; 190(2):181-4. PubMed ID: 11034276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.